MESOPURE®: An original approach aimed at bridging the gap between preclinical and clinical development
While most existing protocols are based on the results of fundamental research, Univercell-Biosolutions’ scientific innovation has been clinically oriented from the outset. This original approach beneficiates of skills required for a clinical application which today represents key advantages for in vitro applications.
Univercell-Biosolutions’ world-leading MESOPURE® technology yields >99% pure cardiovascular progenitors suitable for producing enriched populations of human cardiomyocytes and endothelial cells.
Univercell-Biosolutions uses MESOPURE® technology to develop iPS cell-derived human cardiomyocytes (CM-ONE®) and iPS cell-derived human endothelial cells (ED-ONE®) with the homogeneity and maturity required by the pharmaceuticals industry.
From pluripotent stem cells (hES or hiPS) to early cardiovascular progenitor cells
Mesopure® propose a unique access to millions of human heart
and endothelial cells to optimize the drug discovery process
Key advantages of MESOPURE® technology:
- Homogeneity: Sorting method yielding >99% pure cell populations of cardiovascular progenitors
- Reproducibility: Totally Reproducible and standardized technology
- Regulatory: GMP compatibility